David Shin
InvestorScientific Fellow Strategic Partnering at Debiopharm Innovation Fund · Investor at Dash Fund
New York City
Writes $100K – $5M checks · typically $1.5M
Find your path to David
176 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.
Rachel PhilbinunlockedDavid: together at Universidad de Sevilla (2014)
×4David: together at Universidad de Sevilla
×6David: together at Universidad Autónoma de Madrid
David: together at University of Lausanne - UNIL
About
David Shin is a Scientific Fellow, Strategic Partnering at Debiopharm, working in search and evaluation within oncology. He holds a PhD in neurosciences and has over ten years of experience spanning basic and translational research, data science, and venture capital, with a background in neuroscience and aging as well as investment analysis and strategic planning.
Experience
- DebiopharmScientific Fellow Strategic Partneringcurrent2025 — presentLausanne, Vaud, Switzerland
- Barcelona ActivaStartup Mentor2025
- PIPRABusiness Development2025Zurich, Switzerland
- DebiopharmVenture Capital Analyst Intern2024 — 2025Lausanne, Vaud, Switzerland
- University of Lausanne - UNILAging Postdoctoral researcher2022 — 2024Lausanne, Vaud, Switzerland
- Centro de Biología Molecular Severo Ochoa, CBMSONeuroscience researcher (PhD)2017 — 2022Madrid, Community of Madrid, Spain
- Centro de Biología Molecular Severo Ochoa, CBMSOResearch Associate2015 — 2017Madrid, Community of Madrid, Spain
- cicCartujaResearch Associate2013 — 2015Seville, Andalusia, Spain
Skills & more
RoedoresStart-up VenturesProject ManagementBusiness StrategyMarket Research1Business Development1Start-up Support1Scientific BackgroundMentoringProject TeamsStudy ReportsProject Plans
+12 more
Project LeadershipExternal RelationshipsLiteratureCompetitive IntelligenceInversionesLaboratory SkillsSocial Media CommunicationsPandas (Software)Data AnalysisInglésEspañolLiterature ReviewsLanguages English · French · Italian · Spanish
- Introduction to Drug Hunting — Novartis
- Foundations of Project Management — Google
- Private Equity and Venture Capital — Università Bocconi
- MLOps — Canvas Credentials (Badgr)
- TensorFlow & Keras — Canvas Credentials (Badgr)
- SQL — Canvas Credentials (Badgr)
- Maths for Data Science — Canvas Credentials (Badgr)
- Deep Learning — Canvas Credentials (Badgr)
- Machine Learning Engineer — Canvas Credentials (Badgr)
- Data Wrangling — Canvas Credentials (Badgr)
From David's professional profile.
Colleagues at Debiopharm Innovation Fund
Angela Zubel
Chief Development Officer, Research & Development at Debiopharm Innovation Fund
Bertrand Ducrey
Chief Executive Officer, Debiopharm International & Senior Vice-Chairman, Debiopharm at Debiopharm Innovation Fund
Cedric Odje
Investment Associate at Debiopharm Innovation Fund
Chris Thomas
Director, Investments at Wollemi Capital
Dawid Książczak
Chief Legal Officer at McWin Capital Partners
Frédéric Lévy
Chief Scientific Officer, Search & Evaluation and Scientific Innovation at Debiopharm Innovation Fund
Kavita Patel
Principal at Muus Climate Partners
Kerstin Planitzer-Zipf
Chief Compliance Officer at Cipio Partners
Frequently asked questions
- Who is David Shin?
- David Shin is a Scientific Fellow, Strategic Partnering at Debiopharm, working in search and evaluation within oncology. He holds a PhD in neurosciences and has over ten years of experience spanning basic and translational research, data science, and venture capital, with a background in neuroscience and aging as well as investment analysis and strategic planning.
- Where does David Shin work?
- David Shin is Scientific Fellow Strategic Partnering at Debiopharm Innovation Fund.
- What check size does David Shin write?
- David Shin typically writes checks of $100K – $5M.
- Where did David Shin go to school?
- David Shin studied at The Bridge | Digital Talent Accelerator (Bootcamp in Data Science | Artificial intelligence | Machine Learning); Universidad Autónoma de Madrid (PhD in Molecular Biosciences (Neuroscience), Research); Universidad Autónoma de Madrid (Master in Molecular Biomedicine).
Same school
Also attended The Bridge | Digital Talent Accelerator1
Also attended Universidad Autónoma de Madrid92
Borja FernándezGeneral Partner at Inveready Technology Investment GroupAna MartínezGeneral Partner at Inveready Technology Investment GroupMiguel Garcia DiazVice President for Research, Scholarship and Innovation at University of Delaware at The Innovation SpaceCristina Garcia-MargalloInvestor at KfundRyan GembalaFounder & Managing Partner at Pathbreaker VenturesJulia SalaverríaManaging Partner at Ysios Capital
+ 86 more
Also attended Universidad de Sevilla59
Andrew BrochuController at Castle Island VenturesLauren DenshamPartner, Head of Portfolio Services & Impact at Energize VenturesBorja BreñaPartner at Nauta CapitalRachel PhilbinVice President at Long Ridge Equity PartnersCourtney SawatzkeEarly-stage Investor at Active PartnersCristina GarmendiaGeneral Partner at Ysios Capital
+ 53 more
Also attended Colegio Internacional de Sevilla San Francisco de Paula1
Shared employers
Also worked at Barcelona Activa3
Also worked at PIPRA1
Also worked at Debiopharm8
Marc CikesManaging Director at Debiopharm Innovation FundTom GibbsSenior Investment Director at Debiopharm Innovation FundVincent LepreuxInvestment Principal at Debiopharm Innovation FundTanja DoweManaging Director at Angelini VenturesBertrand DucreyChief Executive Officer, Debiopharm International & Senior Vice-Chairman, Debiopharm at Debiopharm Innovation FundAngela ZubelChief Development Officer, Research & Development at Debiopharm Innovation Fund
+ 2 more
Also worked at University of Lausanne - UNIL12
Yannick RitschelInvestor at Backbone VenturesGregor HirtCIO Multi Asset at Allianz Global InvestorsMaria TahriPrincipal at AlvenLuca MianInnovation Specialist at META GroupSara PicóInvestor at Debiopharm Innovation FundPavel ErmolineHead of Venture Capital and Direct Investing at Moonfare
+ 6 more